资讯日报：普京释放和谈意愿 股票市场概览 港股市场表现 美股市场表现 ⚫ 11月27日，美国感恩节假期休市。 日股市场表现 2025 年 11 月 28 日 资讯日报 海外市场主要股市上日表现 | 指数 | 收盘价 | 日常的 | 周涨跌 | 年初至今 | | --- | --- | --- | --- | --- | | | | (%) | (%) | 消费 | | | | | | (%) | | 恒生指数 | 25.946 | 0.07 | 2.88 | 29.34 | | 恒生科技 | 5.598 | (0.36) | 3.75 | 25.29 | | 恒生国企 | 9.165 | 0.03 | 2.75 | 25.72 | | ┣证指数 | 3.875 | 0.29 | 1.05 | 15.62 | | 日经225 | 50.167 | 1.23 | 3.17 | 25.75 | | 新加坡海峡 | 4.509 | 0.17 | 0.90 | 0.00 | | 标普500 | 6.813 | 0.00 | 3.17 | 15.83 | | 纳斯达克 | 23,215 | 0.00 | 4.23 | 2 ...

野村发表报告指，药明康德强劲研发实力助其把握市场机遇，重申对其"买入"评级，目标价由130.63港 元上调至132.8港元。截至2025财年9月底，公司累计承接3430个项目(其中临床前/I期/II期/III期/商业化 阶段分别为2,889/374/87/80个，为2021年的约3倍)；公司总订单积压达598.8亿元，第三季新签订单年增 32%至153亿元。 ...

每经AI快讯，11月28日，港股创新药概念股震荡走低，药明康德跌超3%，信达生物、翰森制药跌超 2%，中国生物制药、石药集团跌超1%。 ...

Summary of Key Points from China Healthcare Conference and Tour Industry Overview - **Industry**: China Healthcare - **Focus**: Innovation, Globalization, and Recovery in Medical Technology (Medtech) Core Insights 1. **Innovation Hub**: China is establishing itself as a global innovation hub, particularly in novel modalities such as IO bispecific, ADC, and siRNA [1][2] 2. **Medtech Globalization**: Leading Chinese medical equipment companies are moving beyond simple exports to establish localized production and direct sales networks [1][3] 3. **IVD Market Recovery**: The domestic In-Vitro Diagnostics (IVD) market is showing signs of bottoming out, with hospitals incentivized to switch to cost-effective domestic solutions due to pricing pressures [1][4] 4. **CXO Sector Performance**: Strong orders in the CXO sector are sustained, with potential price recovery in domestic clinical CROs expected to improve gross margins in 2026 [1][5] Company-Specific Highlights 1. **Abbisko (2256.HK)** - Focus on clinical progress of irpagratinib and ABSK043, with a strong pipeline that remains undervalued in the market [15] - Irpagratinib's Phase 3 study for HCC is on track, and ABSK043 shows promise in combination therapies [16][17] 2. **Huadong Medicine (000963.SZ)** - Innovative drugs contributed Rmb1,675 million in sales for 9M25, up 62% YoY, with a focus on oncology and metabolic diseases [19] - Ongoing discussions for potential out-licensing of GLP-1 candidates and ADC [20] 3. **MicroPort MedBot (2252.HK)** - YTD overseas orders exceeded 70, indicating rapid commercialization in international markets [23] - Targeting cash flow breakeven in 2026, with a focus on increasing revenue from high-margin consumables [24][25] 4. **Shanghai Fosun Pharma (2196.HK)** - Optimistic about the inclusion of CAR-T therapy Yescarta in the innovative drug catalog of commercial insurance, expected to accelerate coverage [28] - Increasing R&D investment by 20% YoY, focusing on new modalities like radiopharmaceuticals [30] 5. **Henlius (2696.HK)** - HLX43 shows promising data in NSCLC, with plans for multiple registrational trials [31][33] - Developing a new platform for radiopharmaceuticals and small nucleic acids [32] 6. **Shenzhen Mindray (300760.SZ)** - Aiming to double its current 10% market share in IVD within three years, leveraging comprehensive lab solutions [37] - Global strategy focuses on localization and diversification of manufacturing [38] 7. **Tigermed (3347.HK)** - Positive revenue growth guidance for 2025, with strong orders in Phase 1/2 trials [40][42] - Expanding overseas operations, with significant growth in the US and Japan [43] 8. **United Imaging (688271.SS)** - Achieving robust growth in developed markets, with a CAGR of 50% for overseas markets expected [44][48] - Strong positioning in high-end MRI and molecular imaging sectors [47] Additional Insights - **siRNA Modality**: The siRNA field is at an inflection point, attracting significant interest from multinational corporations due to its long-dosing interval potential [2][9] - **Market Dynamics**: The domestic IVD market is experiencing a structural shift favoring domestic leaders, with hospitals seeking cost-effective solutions [4][14] - **Globalization Trends**: Chinese medtech firms are successfully executing globalization strategies, with significant growth in emerging markets [3][13] This summary encapsulates the key takeaways from the China Healthcare Conference and Tour, highlighting the industry's focus on innovation, globalization, and recovery, along with specific insights into leading companies within the sector.

证券研究报告 | 2025年11月26日 2025年11月27日 医药生物周报（25 年第 46 周） 优于大市 化脓性汗腺炎治疗药物梳理 本周医药板块表现弱于整体市场，医药商业板块领跌。本周全部 A 股下跌 4.32%（总市值加权平均），沪深 300 下跌 3.77%，中小板指下跌 5.10%， 创业板指下跌 6.15%，生物医药板块整体下跌 6.88%，生物医药板块表 现弱于整体市场。分子板块来看，化学制药下跌 7.02%，生物制品下跌 7.46%，医疗服务下跌 6.90%，医疗器械下跌 6.38%，医药商业下跌 7.67%，中药下跌 6.46%。医药生物市盈率（TTM）36.69x，处于近 5 年历史估值的 78.22%分位数。 化脓性汗腺炎治疗药物梳理。化脓性汗腺炎（HS）是一种慢性、复发性、 毁容性、炎症性皮肤病。一般认为西方人群的真实患病率~1%，美国确诊 HS 患者~32 万人（其中~20 万为中重度患者）；中国 HS 患病率~0.03%（~40 万人，已被列入第二批罕见病目录），其中中重度患者~30 万人。HS 一线 疗法以抗菌为主，二线生物制剂疗法主要为阿达木单抗（TNFα）、司库奇 尤单抗 ...

两市全天特大单净流出96.75亿元，其中25股特大单净流入超2亿元，中兴通讯特大单净流入10.02亿元， 特大单净流入资金居首。 沪指今日收盘上涨0.29%。资金面上看，沪深两市全天特大单净流出96.75亿元，共计1964股特大单净流 入，2587股特大单净流出。 从申万一级行业来看，今日有8个行业特大单资金净流入，电子特大单净流入规模居首，净流入资金 18.25亿元，该行业指数今日上涨0.26%，其次是轻工制造，今日上涨1.09%，净流入资金为6.25亿元， 净流入资金居前的还有房地产、基础化工等行业。 | 002428 | 云南锗业 | 26.01 | 3.92 | 2.30 | 有色金属 | | --- | --- | --- | --- | --- | --- | | 003009 | 中天火箭 | 58.83 | 10.00 | 2.19 | 国防军工 | | 001309 | 德明利 | 214.18 | -1.46 | 2.16 | 电子 | | 000801 | 四川九洲 | 16.37 | 6.30 | 2.09 | 家用电器 | 特大单净流出资金排名 所属行业来看，上述特大单净流入资金居前 ...

Core Viewpoint - WuXi AppTec (603259.SH) announced a significant change in shareholder equity, with a reduction of 11,827,898 shares, representing 0.40% of the total share capital as of the announcement date [1] Group 1: Shareholder Changes - The company received a notification regarding the reduction of shares held by certain shareholders from 547,539,294 shares to 535,711,396 shares, decreasing their ownership percentage from 18.35% to 17.95% [1][2] - The reduction in shareholding occurred between November 20, 2025, and November 25, 2025, with a weighted average price of 93.571 yuan per share during this period [2] - The total amount of shares sold by the shareholders amounted to approximately 1.107 billion yuan [2]

Summary of Key Points from the Conference Call Industry Overview - The focus is on the **China A-shares market**, specifically the **CSI300 index** and its outlook for 2026. Core Insights and Arguments 1. **CSI300 Target Projections**: - The base-case target for the CSI300 by the end of 2026 is set at **5,200**, based on a **15.9x** P/E ratio and an estimated EPS of **Rmb328**, reflecting a **15% year-on-year growth** [1][4][5]. - Bear-case and bull-case targets are **4,000** and **6,000**, respectively [1][5]. 2. **Investment Themes for 2026**: - **Pro-equity "anti-involution" policies** are expected to enhance structural upside in net profit margin (NPM) and return on equity (ROE) for the CSI300, with consensus estimates of **12% NPM** and **11% ROE** [4]. - **AI Infrastructure Growth**: Anticipated capital expenditure growth in AI infrastructure globally will benefit Chinese suppliers, particularly those focused on localization and AI monetization [4]. - **Global Macro Support**: Easing fiscal and monetary policies globally will support offshore sales for listed companies [4]. - **K-shaped Recovery in Consumption**: This recovery is expected to benefit both low-end and luxury consumption sectors [4]. 3. **Downside Risks**: - Potential cuts to consensus EPS estimates for Q4 2025, especially in the **IT** and **Healthcare** sectors [4]. - The continuation of a "high-quality development" approach may dampen mid-range aspirational consumption [4]. - Geopolitical tensions, particularly between the US and China, could pose risks, especially with upcoming elections [4]. 4. **Potential Policy Changes**: - The onset of a non-performing loan (NPL) cycle may lead to new policies aimed at supporting physical properties [4]. - Increased efficiency from AI and digitalization may necessitate enhanced social security coverage due to job dislocations [4]. 5. **Thematic Stock Screens**: - Focus on **IT and Healthcare A-shares** that demonstrate innovation potential, with metrics such as market capitalization and overseas revenue [4]. - Screening for top A-share listings across various sectors including **autos, battery materials, lithium, solar, cement, chemicals, coal, steel, dairy, hogs, liquor, and logistics** [4][10]. Additional Important Insights - The **CSI300 index** is projected to have an implied upside of **17%** from the current level to the base-case target, while the bear-case scenario indicates a **10% downside** [5]. - The report highlights a shift from value to growth stocks expected by early 2026, particularly in the context of the **IT** and **Healthcare** sectors [4]. - The **A-share market** has shown robust margin financing, indicating strong investor confidence [14]. This summary encapsulates the key points discussed in the conference call, providing a comprehensive overview of the outlook for the China A-shares market and the CSI300 index for 2026.

证券研究报告 | 2025年11月26日 2025年11月27日 医药生物周报（25 年第 46 周） 优于大市 化脓性汗腺炎治疗药物梳理 本周医药板块表现弱于整体市场，医药商业板块领跌。本周全部 A 股下跌 4.32%（总市值加权平均），沪深 300 下跌 3.77%，中小板指下跌 5.10%， 创业板指下跌 6.15%，生物医药板块整体下跌 6.88%，生物医药板块表 现弱于整体市场。分子板块来看，化学制药下跌 7.02%，生物制品下跌 7.46%，医疗服务下跌 6.90%，医疗器械下跌 6.38%，医药商业下跌 7.67%，中药下跌 6.46%。医药生物市盈率（TTM）36.69x，处于近 5 年历史估值的 78.22%分位数。 化脓性汗腺炎治疗药物梳理。化脓性汗腺炎（HS）是一种慢性、复发性、 毁容性、炎症性皮肤病。一般认为西方人群的真实患病率~1%，美国确诊 HS 患者~32 万人（其中~20 万为中重度患者）；中国 HS 患病率~0.03%（~40 万人，已被列入第二批罕见病目录），其中中重度患者~30 万人。HS 一线 疗法以抗菌为主，二线生物制剂疗法主要为阿达木单抗（TNFα）、司库奇 尤单抗 ...

据交易所数据显示，截至11月27日开盘一小时，主力资金流出前20的股票分别为：药明康德（-3.67亿 元）、沪电股份（-2.98亿元）、垒知集团（-2.54亿元）、浪潮信息（-2.48亿元）、永鼎股份（-2.45亿 元）、天华新能（-2.11亿元）、长芯博创（-1.98亿元）、海南瑞泽（-1.97亿元）、三江购物（-1.85亿 元）、遥望科技（-1.83亿元）、天际股份（-1.82亿元）、宁德时代（-1.59亿元）、蓝色光标（-1.52亿 元）、工商银行（-1.51亿元）、中国电影（-1.48亿元）、万 科Ａ（-1.47亿元）、国风新材（-1.42亿 元）、石基信息（-1.42亿元）、美利信（-1.35亿元）、中文在线（-1.34亿元）。 ...